Colesevelam

CHEMBL6068331 Phase 4 Approuvé Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A newer generation bile acid sequestrant that lowers LDL cholesterol by binding bile acids in the intestine and has also been approved for improving blood sugar control in type 2 diabetes. It is better tolerated than older resins and has fewer drug interactions.

Aires thérapeutiques

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A newer generation bile acid sequestrant that lowers LDL cholesterol by binding bile acids in the intestine and has also been approved for improving blood sugar control in type 2 diabetes. It is better tolerated than older resins and has fewer drug interactions.

Yes, Colesevelam is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068331. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.